Cost Effectiveness of Molecular Diagnostic Testing Algorithms for the Treatment Selection of Frontline Ibrutinib for Patients with Chronic Lymphocytic Leukemia in Australia

被引：0
|
作者：
Martin Vu
Koen Degeling
Ella R. Thompson
Piers Blombery
David Westerman
Maarten J. IJzerman
机构：
[1] The University of Melbourne,Cancer Health Services Research, Centre for Cancer Research, Faculty of Medicine, Dentistry and Health Sciences
[2] The University of Melbourne,Cancer Health Services Research, Centre for Health Policy, Melbourne School of Population and Global Health, Faculty of Medicine, Dentistry and Health Sciences
[3] Peter MacCallum Cancer Centre,Pathology Department
[4] The University of Melbourne,Sir Peter MacCallum Department of Oncology
[5] Peter MacCallum Cancer Centre/Royal Melbourne Hospital,Clinical Haematology
[6] Erasmus School of Health Policy and Management,undefined
来源：
Applied Health Economics and Health Policy | 2024年 / 22卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：107 / 122
页数：15
相关论文
共 50 条
  • [1] Cost Effectiveness of Molecular Diagnostic Testing Algorithms for the Treatment Selection of Frontline Ibrutinib for Patients with Chronic Lymphocytic Leukemia in Australia
    Vu, Martin
    Degeling, Koen
    Thompson, Ella R.
    Blombery, Piers
    Westerman, David
    IJzerman, Maarten J.
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2024, 22 (01) : 107 - 122
  • [2] COST-EFFECTIVENESS OF IBRUTINIB AS FRONTLINE TREATMENT FOR ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN BELGIUM
    Smet, A.
    Peng, S.
    Dorman, E.
    Deger, K.
    Sorensen, S.
    Baculae, S.
    Cote, S.
    VALUE IN HEALTH, 2017, 20 (05) : A108 - A108
  • [3] COST -EFFECTIVENESS OF OBINUTUZUMAB AS FRONTLINE TREATMENT FOR UNFIT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN REPUBLIC OF MACEDONIA
    Nestorovska, Kapedanovska A.
    Sterjev, Z.
    Naumovska, Z.
    Grozdanova, A.
    Dimovski, A.
    Suturkova, L.
    VALUE IN HEALTH, 2017, 20 (09) : A736 - A736
  • [4] Spotlight on ibrutinib and its potential in frontline treatment of chronic lymphocytic leukemia
    Khan, Maliha
    Gibbons, Jamie L.
    Ferrajoli, Alessandra
    ONCOTARGETS AND THERAPY, 2017, 10 : 1909 - 1914
  • [5] Ibrutinib in Treatment of Patients with chronic lymphocytic Leukemia
    Flammiger, A.
    ONKOLOGE, 2015, 21 (08): : 732 - 733
  • [6] Cost-Effectiveness of Ibrutinib as First-line Treatment for Older Patients With Chronic Lymphocytic Leukemia in Iran
    Fariman, Soroush
    Nasab, Fatemeh Momeni
    Faraji, Hoda
    Afzali, Monireh
    VALUE IN HEALTH REGIONAL ISSUES, 2023, 38 : 93 - 100
  • [7] Cost-Effectiveness of Ibrutinib for Chronic Lymphocytic Leukemia Treatment in India: Is Evidence Really at Crossroads?
    Jyani, Gaurav
    Gupta, Nidhi
    VALUE IN HEALTH REGIONAL ISSUES, 2024, 42
  • [8] Challenges in the Frontline Treatment of Patients With Chronic Lymphocytic Leukemia
    Nicole Lamanna
    Current Hematologic Malignancy Reports, 2010, 5 : 45 - 51
  • [9] Challenges in the Frontline Treatment of Patients With Chronic Lymphocytic Leukemia
    Lamanna, Nicole
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2010, 5 (01) : 45 - 51
  • [10] Cost Effectiveness of Zanubrutinib Versus Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
    Kang, Dong-Won
    Wang, Li
    Short, Nicholas J.
    Ferrajoli, Alessandra
    Wang, Yucai
    Zhou, Shouhao
    Shen, Chan
    PHARMACOECONOMICS, 2024, 42 (04) : 409 - 418
12345